Igrene (ABI) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
13 Jun, 2025Executive summary
Net loss after financial items was -5,202 KSEK for the year, compared to -3,203 KSEK the previous year.
Strategic focus is on extracting carbon and hydrogen from methane deposits in Siljansringen, with new technology partnerships and EU support sought.
No dividend proposed for 2023/2024.
Financial highlights
Revenue for the year was 255 KSEK, mainly from asset sales, compared to 3 KSEK last year.
Operating loss was -5,204 KSEK, up from -2,967 KSEK year-over-year.
Earnings per share was -0.10 SEK, compared to -0.06 SEK last year.
Cash and cash equivalents at year-end were 972 KSEK, down from 4,210 KSEK.
Equity at year-end was 19,002 KSEK, down from 24,205 KSEK.
Outlook and guidance
Plans to apply for environmental permits in autumn 2024 for a demonstration plant producing carbon and hydrogen.
Ongoing efforts to secure EU funding for technology development and demonstration facility.
Anticipates constructive dialogue with authorities regarding use of biogenic methane.
Latest events from Igrene
- Losses narrowed, liquidity improved, and strategic focus is on renewable methane conversion.ABI
Q1 202616 Jan 2026 - Wider losses and zero revenue, but strengthened equity after rights issue; regulatory hurdles persist.ABI
Q4 202517 Oct 2025 - Regulatory setbacks halted project progress despite strong liquidity and high equity ratio.ABI
Q3 202518 Jul 2025 - Quarterly loss increased as Igrene advances emission-free hydrogen and carbon plans.ABI
Q3 202413 Jun 2025 - Losses increased and demo plant delayed, but equity and cash position strengthened.ABI
Q2 20256 Jun 2025 - Losses increased but cash strengthened after rights issue; focus on green hydrogen tech.ABI
Q1 20256 Jun 2025